Nash results b4 end of month. Results will just meet most...

Nash results b4 end of month. Results will just meet most endpoint targets but won't indicate any reduction in fatty liver. Consequently SH reaction will show disappointment & the SP will drop below 17 cents. However, C-diff will ultimately rescue Immuron albeit 2 years down the track. Travelan sales will grow slowly partly supporting the companies monthly burn-rate. DOD will eventually bolster sales driving SP up after a successful DOD trial. (I have no idea what that might be but I would think it would be a fairly protracted exercise to establish the required /desired endpoint results).
My money is on C-diff being the block-buster because of better than proof of concept results although recruitment of trial patients will be longer than anticipated.
Those of us that choose to hold onto our stock will reap the greatest rewards but the short term will be painful.
Remember, just my thoughts. Would be interested in other SH thoughts.

Hang tight.

Cheers